Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature

Yang, Qing-Xu; Pei, Xiao-Juan; Tian, Xiao-Ying; Li, Yang; Li, Zhi

doi:10.1186/1746-1596-7-7

Table 1 Clinicopathological features of patients with AITL-developed secondary EBV-associated B cell lymphoma described in present and previous reports

From: Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature

caseNo.	Authors (yr.)	Age/sex	Tumor site		Interval (mo)	Histotype of BCL*	Treatment		Clinical Outcome
			AITL	BCL			AITL	BCL
1	Abruzzo LV (1993) [4]	46/M	LN	SK	26	Large-cell immunoblastic type	Cyclophosphamide	N/D	Died of multiorgan failure
2	Park S (2002) [5]	55/F	LN	LN	48	BCL	CHOP	CHOP-R	CR and alive 12 mo later
3	Xu Y (2002) [6]	48/F	LN	LN	0	DLBCL	CHOP and ESHAP		CR and relapsed a few months later
4	Zettl A (2002) [7]	68/M	LN	ST	34	DLBCL	Observation	Glucocorticoids	Died 4 mo later of tuberculosis
5		47/M	LN	LN	29	DLBCL	CC; BMT	CC; involved field radiation	Died 3 mo later of Aspergillus pneumonia
6		61/M	LN	LN	96	Plasmacytoma	N/Av	N/Av	Alive with disease 24 mo later
7	Hawley RC (2006) [8]	69/F	LN	SK	56	DLBCL	CHOP	R-hyperCVAD	Died 54 mo later
8	Attygalle AD (2007) [9]	28/M	LN	BM	24	DLBCL	CHOP	Gemcitabine	No response and died 3 mo later
9		60/F	LN	LN	8	DLBCL	CHOP	CHOP-Et	No response and died 3 mo later
10		59/M	LN	LN	8	DLBCL	N/Av	CC	PR and alive with disease 68 mo later
11		72/M	LN	LN	84	DLBCL	N/Av	N/Av	N/A
12		78/F	LN	LN	0	DLBCL	Thalidomide		PR
13	Willenbrock K (2007) [10]	76/F	LN	LN	8	DLBCL	N/Av	N/Av	N/Av
14		46/F	LN	BM	5	DLBCL	N/Av	N/Av	N/Av
15		84/M	LN	LN	0	DLBCL	N/Av	N/Av	N/Av
16		72/M	LN	LN	0	DLBCL	N/Av	N/Av	N/Av
17		65/M	LN	LN	0	CD30-positive BCL	N/Av	N/Av	N/Av
18		60/F	LN	LN	0	DLBCL	N/Av	N/Av	N/Av
19	Weisel KC (2008) [11]	59/M	LN	DB and lung	11	DLBCL	Fudarabine+ CHOP	N/D	Died 2 weeks later
20	Takahashi T (2010) [12]	66/F	LN	Ileum	24	DLBCL	THPCOP CHASE	N/D	Died 1 mo later of respiratory failure
21	Skugor ND (2010) [13]	36/F	LN	LN	11	DLBCL	FED	CHOP-R and stem cell transplantation	CR
22	Huang J (2011) [14]	64/M	LN	LN	47	DLBCL	IHOP	CHOP-R	Alive with disease 13 mo later
23	Present case	65/M	LN	SK	19	DLBCL	CHOP	CHOP-R	PR

*, all B-cell lymphoma with EBV positive; AITL, angioimmunoblastic T-cell lymphoma; BCL, B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; LN, lymph node; SK, skin; ST, soft tissue; BM, bone marrow; DB, Duodenal bulbus; Interval 0, AITL with simultaneous B-cell lymphoma or primary B-cell lymphoma in the background of AITL; BMT, bone marrow transplantation; N/Av, not available; N/D, not done; PR, partial response; CR, complete remission; CHOP, cyclophosphamide, vincristine, adriamycin, and prednisone; ESHAP, etoposide, methyl prednisolone, cytarabine (ara-C) and cisplatin; hyperCVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; IHOP, ifosfamide, doxorubicin, vincristine, and prednisone; THPCOP, cyclophosphamide, pirarubicin, vincristine, prednisolone; CHASE, cyclophosphamide, cytarabine, etoposide, dexamethasone; FED, fludarabine, cyclophosphamide, dexamethasone; Et, etoposide; R, rituximab; CC, combination chemotherapy, details not available;

Back to article page

ISSN: 1746-1596

Contact us

Submission enquiries: journalsubmissions@springernature.com

Diagnostic Pathology

Contact us